GeneDx Holdings Corp.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M |
| Cost of revenue | $129.4M | $111.1M | $112.6M | $261.4M | $228.8M |
| Gross profit | $298.2M | $194.4M | $90.0M | -$26.8M | -$16.6M |
| Research and development | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M |
| Operating income | -$13.1M | -$23.2M | -$180.6M | -$667.7M | -$446.1M |
| Interest expense | — | — | — | $3.2M | $2.8M |
| Pretax income | -$21.1M | -$52.6M | -$176.7M | -$598.0M | -$245.4M |
| Income tax expense | -$116,000 | -$343,000 | -$926,000 | -$49.1M | $0 |
| Net income | -$21.0M | -$52.3M | -$175.8M | -$549.0M | -$245.4M |
| Balance Sheet | |||||
| Cash and equivalents | $105.0M | $85.2M | $99.7M | $123.9M | $400.6M |
| Current assets | $268.3M | $198.0M | $182.3M | $212.6M | $483.5M |
| Total assets | $523.7M | $419.4M | $418.8M | $490.9M | $554.1M |
| Current liabilities | $108.9M | $54.8M | $58.8M | $144.3M | $101.3M |
| Total liabilities | $215.5M | $174.1M | $190.7M | $237.2M | $166.0M |
| Stockholders' equity | $308.2M | $245.2M | $228.0M | $253.7M | $388.1M |
| Cash Flow Statement | |||||
| Cash from operations | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M |
| Depreciation and amortization | $9.6M | $7.9M | $19.7M | $50.0M | $21.8M |
| Stock-based compensation | $32.2M | $9.1M | $326,000 | $42.0M | $219.4M |
| Capital expenditure | $19.0M | $5.5M | $5.2M | $7.2M | $9.4M |
| Free cash flow | $14.3M | -$34.0M | -$185.4M | -$326.3M | -$199.8M |
| Impairments | $0 | $0 | $10.4M | $210.1M | $0 |
Shares outstanding 29.7M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.